April 24, 2012 (Prague, Czech Republic) — A gene-expression test for impending cardiac transplant rejection, shown in several US-based trials to have a high negative predictive value that could help ...
Paris & Strasbourg, France - May 25, 2016 - DIAXONHIT (Alternext: ALEHT, FR0004054427), the leading French provider of specialty in-vitro diagnostic solutions for transplantation, infectious diseases ...
This transplant test is facing a death sentence unless a rejection is on the horizon. Its manufacturer warns that it will have to stop selling its commonly used blood test for detecting imminent organ ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive gene expression ...
BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive tests to monitor ...
September 14, 2010 (San Diego, California) — Heart-transplant patients prefer the AlloMap (XDx, Brisbane, CA) gene-expression profiling test over routine endomyocardial biopsy, probably because it ...
Clinical utility and performance of the AlloMap ® heart transplant test confirmed in European study CARGO II clinical study confirms performance of AlloMap® in European patients New opportunities for ...
A heart transplant is the removal of a diseased heart and replacement with a donor heart from someone who has just died (the donor). According to the Organ Procurement and Transplantation Network ...
BRISBANE, Calif., Sept. 22, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically ...
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of ...
XDx, Inc. announced the launch of AlloMap® Molecular Expression Testing in Germany. AlloMap is XDx’s easy and convenient, non-invasive blood test that aids physicians in determining a stable heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results